Ophthalmology is no longer a peripheral category. It is emerging as one of pharma’s most durable growth engines.

Demand is rising for clear structural reasons. Populations are ageing. Diabetes is increasing. Chronic retinal disease and glaucoma require sustained treatment, not one-off correction. That creates predictable, long-term prescription markets.

At the same time, innovation is accelerating. Advanced retinal therapies, dual-pathway mechanisms and extended-interval delivery platforms are raising the bar on efficacy while reducing treatment burden.

Download Free Sample Report (incl. forecasts and methodology)

Structural Shifts Redefining Market Positioning

The market is consolidating around global players able to combine biologic expertise with scalable delivery infrastructure. Asia-Pacific remains the fastest-growing region, adding both expansion potential and competitive intensity.

Capital is concentrating in franchises offering extended dosing intervals, defensible intellectual property and strong regulatory execution. Success will hinge on the ability to scale innovation while protecting margin and access.

According to Visiongain analysis, the global ophthalmic drugs market is forecast to grow from US$41.88 billion in 2026 to US$89.17 billion by 2036, representing a CAGR of 7.9 percent.

Four structural shifts are shaping this trajectory:

• Interval extension is the benchmark: Longer-acting molecules are extending dosing schedules in retinal disease and glaucoma, improving real-world adherence and strengthening revenue persistence.
• Multi-pathway targeting is raising entry barriers: Combined anti-VEGF and anti-inflammatory approaches are delivering stronger disease control, making incremental innovation insufficient.
• Delivery innovation is altering economics: Implants, injectable depots and nanocarrier systems sustain therapeutic levels for months, supporting premium pricing and reducing clinic reliance.
• Biologic platforms are capturing share: Monoclonal antibodies and protein-based therapies continue to displace legacy treatments, concentrating value in specialist retinal care.

Biologics Innovation: The New Battleground in Ophthalmology

Biologic platforms now shape competitive dynamics in ophthalmology, driven by extended dosing intervals, multi-pathway efficacy and integrated delivery systems.

Roche and Genentech’s faricimab combines VEGF and Ang-2 inhibition to extend treatment schedules and improve retinal outcomes. Regeneron and Bayer’s high-dose aflibercept HD reinforces franchise positioning through longer intervals between injections. Roche’s Susvimo pairs biologics with implantable sustained release technology to reduce injection frequency. AbbVie’s izervay expands advanced retinal therapy into geographic atrophy, a previously underserved segment.

Emerging therapies such as Oculis’ OCS 01 and LENZ Therapeutics’ VIZZ show how delivery innovation is broadening ophthalmology beyond traditional intravitreal models.

These developments are consolidating market control among a limited group of players and intensifying competition for high-value retinal franchises. Longer dosing intervals strengthen physician loyalty, reinforce payer positioning and raise switching barriers. As extended-interval performance becomes expected, new entrants must match both efficacy and schedule flexibility to compete.

Visiongain insight: Biologic platforms are redefining ophthalmology through interval extension, multi-pathway action and delivery integration. Market control increasingly depends on expanding indications, embedding delivery innovation and defending high-value retinal franchises.

Long-Acting Delivery Platforms: Biologics at the Centre of Ophthalmology’s Next Phase

Long-acting delivery is becoming a defining strategic differentiator. Traditional intravitreal biologics required monthly administration. New platforms sustain therapeutic levels for months, reducing treatment burden while maintaining efficacy and improving treatment persistence. This shift supports premium pricing, strengthens physician preference and enhances revenue durability.

Faricimab’s extended dosing schedule of up to 16 weeks sets a new performance benchmark. High-dose aflibercept HD reinforces this direction by stretching injection intervals. Susvimo represents a step change, delivering ranibizumab continuously through an implanted reservoir. AbbVie’s izervay expands the use of biologics into new retinal indications, while EyePoint’s depot technologies demonstrate how sustained-release systems integrate biologics into advanced delivery formats.

These advances are not incremental. They represent a structural shift in how chronic eye disease is treated and monetised. Implantable and depot platforms introduce device integration, surgical workflow and manufacturing complexity, raising capital thresholds and strengthening franchise defensibility as treatment intervals lengthen.

Visiongain insight: Delivery innovation amplifies the value of biologics. Reduced dosing frequency, revenue persistence and scalable platform integration are becoming central to retinal market positioning.

Consolidation in Ophthalmology: A Marker of Market Maturity

Between 2024 and 2026, consolidation in ophthalmology has become more targeted, with capital flowing toward defensible retinal franchises.

Rather than broad diversification, companies are reinforcing biologic depth and delivery capability where scientific complexity and pricing power are highest. With fewer clearly differentiated late-stage assets available, valuations have concentrated around platforms offering extended dosing intervals and strong intellectual property. For emerging companies, partnership is increasingly structural rather than optional.

Roche has strengthened its position with faricimab and Susvimo. Regeneron and Bayer have deepened collaboration around aflibercept HD. AbbVie has expanded into geographic atrophy with izervay. Meanwhile, EyePoint and Oculis are leveraging partnership models to accelerate sustained-release and topical biologic platforms.

The pattern of deal activity signals a market that is maturing yet still innovation-led. Advantage increasingly depends on scientific depth, delivery integration and disciplined capital allocation into durable retinal franchises.

Visiongain insight: Ophthalmology has entered a phase where portfolio breadth matters less than biologic expertise, delivery capability and capital discipline.

Market Outlook: Durability, Scale and Capital Discipline

Demand is being shaped by long-term demographic and clinical trends. Ageing populations, growing diabetes prevalence and earlier diagnosis are steadily increasing the number of patients treated for retinal disease, with momentum expected to persist through 2036.

Growth is unlikely to be evenly distributed. It will concentrate on platforms offering extended dosing schedules, multi-pathway efficacy and integrated delivery systems. Longer treatment schedules strengthen franchise stability and raise switching barriers, while implantable and depot technologies increase capital intensity, favouring organisations with regulatory depth and manufacturing scale.

Advances in AI-assisted retinal imaging and earlier disease detection are expected to expand the pool of treated patients, reinforcing long-term demand for advanced retinal biologic platforms.

Competition is shifting from molecule innovation alone to platform durability and execution capability. Companies that align biologic science, delivery infrastructure, and disciplined capital allocation will define the next phase of expansion. Incremental differentiation will become harder to monetise as performance benchmarks rise.

Visiongain insight: The ophthalmic drugs market is entering a durability-driven phase. Value will increasingly concentrate in extended-interval biologic platforms supported by strong intellectual property, delivery integration and capital discipline. Control of high-value retinal franchises will determine long-term competitive positioning.

Related Market Reports

Detailed market forecasts, competitive analysis, and sector reports help you make clear, future-proof strategic choices across R&D, manufacturing, supply chain, and commercial execution.

Download Free Sample Report (incl. forecasts and methodology)

Explore the latest strategic market reports:

• Ophthalmic Drugs Market Report 2026-2036
• Anti-obesity Drugs Market Report 2026-2036
• Longevity Market Report 2026-2036
• Alzheimer’s Therapeutics Market Report 2026-2036
• Rheumatoid Arthritis Drugs Market Report 2026-2036
• Precision Medicine Market Report 2025-2035

Press & Media Enquiries

For commentary, data requests or interview enquiries, please contact: press@visiongain.com